Table 2.
sE-cad can be found in the fluids of patients with multiple conditions
| Patient diagnosis | Type | sE-cad correlates with: | Source | sE-cad Levels (ng/mL) | Ref # |
|---|---|---|---|---|---|
|
| |||||
| Cancer | Bladder | Cancer, grade, number, recurrence | Serum | N: 1013 C: 3955 |
(75) |
| Cancer | Urine | N: .516 mg/mol C: 1.536 mg/mol |
(76) | ||
| Cancer, grade | Urine | N: 1.306 +/− 1.249 mg/mol C: 3.724 +/− 1.892 mg/mol |
(77) | ||
| Recurrence | R: 10.497 +/− 7.47.1 mg/mol | ||||
|
| |||||
| Colorectal | Cancer, Progression | Serum | N1: 3467 B1: 5248 C1: 5495 |
(79) | |
| Not significant | Serum | N: 3.53 C: 3.17 |
(78) | ||
|
| |||||
| Esophageal squamous cell carcinoma | Survival (surgery only) | Serum | PreOp: 5108.96 PreCRT: 3688.932 PostCRT: 3981.029 |
(80) | |
|
| |||||
| Gastric | Cancer | Serum | N: 2515 +/− 744 C: 4735 +/− 2310 |
(81) | |
| Cancer | Serum | N: 5616 C: 9344 |
(82) | ||
| Recurrence | Serum | sE-cad above 10000 | (83) | ||
| Survival | Serum | sE-cad above 10000 | (84) | ||
| Cancer | Serum | N: 2000 C: 3510 +/− 1790 |
(72) | ||
|
| |||||
| Liver | Cancer | Serum | N: 2000 C: 5550 +/− 3110 |
(72) | |
| Cancer | Serum | N: 5798 C: 10759 |
(87) | ||
| Recurrence (early) | sE-cad above 8000 | (87) | |||
|
| |||||
| Non-epithelial | |||||
| Leimyosarcoma | Cancer | Serum | N: 2000 C: 3280 +/− 720 |
(72) | |
| Leukemia | Cancer | Serum | C: 2520 +/− 1000 | (72) | |
| Multiple Myeloma | Cancer | Serum | N: 622.9 C: 3291.4 |
(88) | |
| Survival | Serum | s-Ecad above 3000 | (88) | ||
|
| |||||
| Non-small cell lung | Cancer | Serum | N: 1015 C: 3455 |
(89) | |
| Metastasis | Serum | L2: 2487.8 M2: 4422.2 |
(89) | ||
| Cancer | Serum | N: 1015 +/− 125 NSCL: 3455 +/− 1082.4 SCLC: 3428.3 +/− 1198.8 |
(90) | ||
| Metastasis | Serum | L NSCL: 2460 +/− 388.2 M NSCL: 4579.5 +/− 279.3 L SCLC: 3035 +/− 586.9 M SCLC: 3871 +/− 77.7 |
(90) | ||
|
| |||||
| Ovarian | Not significant | Serum | Luteal cyst: 3677 Dermoid tumor: 2325 Cystadenoma: 2200 C: 2250 |
(92) | |
| Cancer | Cyst | Luteal cyst: 2035 Dermoid tumor: ND Cystadenoma: 2000 C: 14500 |
(92) | ||
| Malignant ascites | Ascites | N: 2061 +/−1968 C: 12241 +/−5314 |
(27) | ||
| Present in ascites | Ascites | C: 89.96 (ug/ul)/ug total protein | (30) | ||
|
| |||||
| Prostate | Cancer, metastasis | Serum | N: 6.270 ug/l L: 9.460 ug/l M: 27.490 ug/l |
(74) | |
|
| |||||
| Skin | |||||
| Basal cell | Not significant | Serum | N: 808 +/− 272 C: 879 +/−485 |
(94) | |
| Melanoma | Cancer, rising S100 | Serum | N: 3198 C: 4975 |
(15) | |
| Cancer, metastasis | Serum | N: 808 +/− 272 M: Values not reported |
(94) | ||
| Paget’s disease | Invasion | Serum | C: Not reported | (94) | |
| Squamous cell | Not significant | Serum | C: 838 +/− 374 | (94) | |
|
| |||||
| Non-cancer | Acute pancreatitis | Severe cases | Serum | N: 5181 +/− 1350 D: 17780 +/− 7853 |
(95) |
|
| |||||
| Benign prostatic hyperplasia (BPH) | BPH | Serum | N: 6.27 ug/l B: 7.26 ug/l |
(74) | |
|
| |||||
| Diabetes | Not significant | Serum | N: 2000 D: 2330 +/− 1580 |
(72) | |
| Not significant | Urine | N: 652.7 +/−87 Diabetic: 721.9 +/−93 |
(96) | ||
|
| |||||
| Diabetic nephropathy (DN) | Nephropathy | Urine | N: 652.7 +/−87 DN0: 721.9 +/−93 DN1: 2751.5 +/− 164 DN2: 5839.6 +/− 428 |
(96) | |
|
| |||||
| Inflammatory skin diseases | (94) | ||||
| Psoriasis | Severe cases | Serum | Values not reported | ||
| Dermatitis | Severe cases | Serum | Values not reported | ||
|
| |||||
| Infection | HIV | Viral load | Plasma | Values not reported | (73) |
|
| |||||
| Hepatitis | Not significant | Serum | N: 2000 D: 2340 +/− 520 |
(72) | |
|
| |||||
| Organ dysfunction | Multi-organ | Sepsis, organ dysfunction | Serum | N: 3280 D: 6000 |
(66) |
|
| |||||
| Cholesystectomy | Inflammation | Serum | Lap: 1850 +/− 250 Open: 3110 +/− 330 |
(67) | |
N: normal, C: cancer, M: metastatic D: disease, R: recurrence, NR: No recurrence, PreOp: Preoperative. CRT: neoadjuvant chemoradiation therapy. L: localized, M: metastatic, ND: not detected, NSCL: non-small cell lung cancer. SCLC: small cell lung cancer. DN0: diabetic, no nephropathy, DN1: diabetic nephropathy, microalbuminuria, DN2: diabetic nephropathy, macroalbuminuria, Lap: laparoscopic
1
Value conversion from log (sE-cad ng/ml) to sE-cad ng/ml by Grabowska and Day.
2
Observation reported by study’s author, but numbers generated by Grabowska and Day.